Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subject with Schizophrenia

Next Previous
X
Search
Trial Profile

A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subject with Schizophrenia

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 20 May 2021 Results of post-hoc analyses evaluating relationship of SF-12 as an outcome measure of HRQOL in patients with schizophrenia, presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 25 Sep 2020 According to an Janssen media release, the company has obtained approval of paliperidone palmitate (Zeprion TRI) Suspension Intramuscular long-acting injection with a 12-week interval in Japan for the treatment of schizophrenia .
    • 15 Sep 2020 Results comparing safety risks in clinical trials of PP3M and PP1M, presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top